To investigate the link between EMT and a CSC phenotype in docetaxel‐resistant prostate cancer cells, we determined the expression of the CSC marker CD44 and identified an increased expression in both the PC‐3 D12 and DU145 R docetaxel‐resistant sublines compared to parental controls (Fig. 5A). This evidence concerns the gene CD44 and prostate carcinoma.